1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Just What We Were Looking For: Roche Pays €70m For Preclinical Anti-CD25 Asset

 
• By Eleanor Malone

Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics. Roche sees combo future for Tusk’s cancer immunotherapy with its own portfolio. Total deal value could reach €655m.

Choosing the key to success from hanging keys concept for aspirations, achievement and incentive
Roche hopes Tusk holds the Treg depletion key • Source: Shutterstock

A little-known company based in the Stevenage Bioscience Catalyst between London and Cambridge, UK, has been acquired by Roche for €70m plus up to €585m in milestone payments. Roche says it may use Tusk Therapeutics’ asset in combination with its approved checkpoint inhibitor Tecentriq (atezolizumab), and could evaluate other combinations in the future.

Roche bought the company for its anti-CD25 antibody, which is designed to target regulatory T-cells (Tregs)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

More from Anticancer

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.